Peter H. O'Donnell, MD, specializes in the treatment of genitourinary malignancies, including prostate, kidney, and testicular cancers — with particular expertise in bladder cancer.
Dr. O'Donnell is a well-published researcher with advanced training in pharmacology and pharmacogenomics (the study of genetic traits that cause differences between patients in drug responses and side-effects). He has an interest in the study of personalized medicine, which involves considering each patient's genetic profile when determining chemotherapy and other therapeutic decisions. Dr. O'Donnell has several ongoing research projects. Currently, he is investigating how genetic factors affect chemotherapy drug outcomes — specifically for patients receiving treatment for bladder cancer, and for patients receiving the widely used chemotherapy drugs cisplatin and capecitabine.
Additionally, Dr. O'Donnell serves as principal investigator of numerous clinical trials, including the "1200 Patients Project," a clinical study operated through the Center for Personalized Therapeutics at the University of Chicago. In this role, he leads an initiative exploring the benefit of incorporating broad pharmacogenomic testing into routine clinical practice for patients with any type of disease.
Dr. O'Donnell is also a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. This committee aims to expand the educational mission of conducting research and training the next generation of scientists in clinical pharmacology, principles of therapeutics, molecular pharmacology, and pharmacogenomics.
Dr. O'Donnell is a well-published researcher with advanced training in pharmacology and pharmacogenomics (the study of genetic traits that cause differences between patients in drug responses and side-effects). He has an interest in the study of personalized medicine, which involves considering each patient's genetic profile when determining chemotherapy and other therapeutic decisions. Dr. O'Donnell has several ongoing research projects. Currently, he is investigating how genetic factors affect chemotherapy drug outcomes — specifically for patients receiving treatment for bladder cancer, and for patients receiving the widely used chemotherapy drugs cisplatin and capecitabine.
Additionally, Dr. O'Donnell serves as principal investigator of numerous clinical trials, including the "1200 Patients Project," a clinical study operated through the Center for Personalized Therapeutics at the University of Chicago. In this role, he leads an initiative exploring the benefit of incorporating broad pharmacogenomic testing into routine clinical practice for patients with any type of disease.
Dr. O'Donnell is also a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. This committee aims to expand the educational mission of conducting research and training the next generation of scientists in clinical pharmacology, principles of therapeutics, molecular pharmacology, and pharmacogenomics.
Specialties
Areas of Expertise
- Genitourinary Cancers
- Bladder Cancer
- Prostate Cancer
- Kidney Cancer
Board Certifications
- Medical Oncology
Memberships & Medical Societies
- American Association for Cancer Research
- American Urological Association
- American Society for Clinical Pharmacology and Therapeutics
- American Society of Human Genetics
- American Society of Clinical Oncology
Languages Spoken
- English
Medical Education
- University of Chicago Pritzker School of Medicine
Internship
- UNC Medical Center
Residency
- University of Chicago Medicine
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Afatinib in Advanced Refractory Urothelial Cancer
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
- Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
- The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
- Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
- A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
- Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
- S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
- A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
- UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
- A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient